HKHasan Kurter

Hasan Kurter

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hasan Kurter has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Epigenetic potentiation of 5-fluorouracil by HDAC inhibitor quisinostat enhances antitumor effects in colorectal cancer

    by Gizem Calibasi-Kocal, Hasan Kurter, Eylem Doga Nartas, Ender Berat Ellidokuz, Yasemin Basbinar

    Histone deacetylase (HDAC) inhibitors have emerged as promising epigenetic therapeutics in cancer treatment; however, their clinical efficacy in solid tumors remains limited. Quisinostat is a potent pan-HDAC inhibitor with demonstrated anticancer activity in various malignancies. This study evaluates the therapeutic potential of Quisinostat, in combination with 5-fluorouracil (5-FU), in colorectal cancer (CRC) cell lines. The effects of Quisinostat and 5-FU, as monotherapies and in combination, were investigated in HCT-116 and HT-29 CRC cell lines. H3K27 acetylation levels were assessed by immunofluorescence to evaluate epigenetic modulation. Cell viability, IC50 shifts, and proliferation were measured using resazurin assays and Ki-67 staining. Apoptosis and mitochondrial membrane potential (ΔΨm) were analyzed via Hoechst 33342/PI dual staining and JC-1 assays. Migration and epithelial-mesenchymal transition (EMT) phenotypes were evaluated through wound healing assays and E-cadherin/N-cadherin immunostaining. Quisinostat significantly increased H3K27 acetylation and enhanced the cytotoxic effect of 5-FU by lowering its IC50 in both cell lines. The combination treatment markedly suppressed proliferation, as evidenced by reduced Ki-67 expression. Quisinostat in combination with 5-FU significantly enhanced ΔΨm loss and apoptotic cell death. Furthermore, the combination treatment inhibited cell migration and reversed the EMT phenotype by increasing E-cadherin and decreasing N-cadherin expression. Quisinostat enhances the antitumor efficacy of 5-FU in CRC cells by promoting histone acetylation, augmenting cytotoxic and apoptotic responses, and reversing EMT-associated migratory phenotypes. These findings support the potential of Quisinostat as an effective adjunct to 5-FU-based chemotherapy in CRC.


  • Combined inhibition of the FAK-Rho-ROCK signaling cascade, one of the important players in mechanotransduction, in colorectal cancers

    by Serap Türkmen, Caner Karaca, Hasan Kurter, Nurçin Kayacık, Gizem Çalıbaşı Koçal, Yasemin Başbınar

    Purpose: Colorectal cancer (CRC) is one of the most common cancer types globally, with a high mortality rate. The FAK-Rho-ROCK successive signaling cascade promotes growth, migration and invasion of cancer cells. Focal adhesions are major sites of interactions between extracellular mechanical environments and intracellular biochemical signaling molecules/cytoskeleton and therefore focal adhesion proteins have been proposed to play important roles in mechanotransduction. This study aims to evaluate the effects of combination treatments with Focal Adhesion Kinase (FAK), Rho-ROCK, and YAP/TAZ inhibitors on the proliferative and epithelial-mesenchymal transition (EMT)-related metastatic characteristics of colorectal cancer cells. Material and Methods: In vitro experiments were performed using the HCT-116 colon cancer cell line. The effects of Y-15 (FAK inhibitor), ROCK inhibitor-2, and YAP/TAZ inhibitor-2, either applied alone or in combination, on cell proliferation were analyzed using the WST-1 cell viability assay. Epithelial-mesenchymal transition (EMT) markers, E-cadherin and N-cadherin, were evaluated via immunofluorescence staining, and fluorescent intensity was analyzed using ImageJ software. Results: Y-15, when applied alone or in combination with other inhibitors, significantly reduced cell proliferation (p≤0.005). Moreover, the combination of Y-15 and ROCK inhibitor-2 increased E-cadherin levels while decreasing N-cadherin levels (p≤0.0159, p≤0.0286). While the effect of YAP/TAZ inhibitor-2 alone was limited, specific effects were observed in combination treatments. Conclusion: This study demonstrates the potential of FAK-Rho-ROCK pathway inhibitors in the treatment of colorectal cancer. The ability of Y-15, in particular, to inhibit cell viability/proliferation and metastatic processes suggests that combination strategies targeting these pathways could contribute to the development of new therapeutic approaches for CRC.


  • Tissue Processing and Isolation of Tumor Cells from Human Colorectal Cancer Tissue

    by Ender Berat Elli̇dokuz, Tolga Sever, Gizem Çalibaşi Koçal, Aras Emre Canda, Sulen Sari̇oglu, Hasan Kurter, İlhan Öztop, Yeşim TUNÇOK, Yasemin Başbinar

    Background: Investigation for research on the cellular biology and physiology of colon cancer tissues requires viable dissociation of single cells. The amount of tissue and dissociation methods can affect the amount of single cell viability. Inadequate initial tissue has negative effects on data quality by resulting in insufficient quality and the number of cells. Methods: In the context of this study different-weigh and different-textured colon tumor tissues have been evaluated to emphasize the importance of initial tissue properties during the operation of tissue processing and cell isolation success. Necrotic areas were also evaluated with the isolated viable cells and the success of 3D primary culture. Results: Elevated weight of the tissue resulted with more total isolated cells. Necrotic tissues caused low percentage of viable cells. Since resected tissues were bigger than biopsy samples, resected tissues derived primary 3D culture were succesfully maintained the culture. Conclusion: To conclude, isolated cells from the bigger and non-necrotic tumor tissues showed better growth pattern for 3D cultures. On the other hand, size was found as a crucial parameter for obtaining more viable cancer cells.


  • Drug Resistance Mechanisms on Colorectal Cancer

    by Hasan Kurter, Janberk Yeşi̇l, Ezgi Daskin, Gizem Çalibaşi Koçal, Hülya Elli̇dOkuz, Yasemin Başbinar

    Standard treatment for colorectal cancer includes surgery, radiotherapy, and chemotherapy. Conventional chemotherapeutic agents used in colorectal cancer such as 5-fluorouracil, capecitabine which is oral form of 5-fluorouracil, irinotecan, and oxaliplatin. One of the major challenges in chemotherapy considered as drug resistance. Drug resistance occurs in many different mechanisms such as alteration in tumor microenvironment, growth kinetics, genetic variations, and tumor heterogeneity. These cytotoxic agents are used in combination form to overcome drug resistance on colorectal cancer. They can also be used in combination with cytotoxic agents as bevacizumab and cetuximab. Combination therapy depends on tumor burden, type, stage, and molecular characteristics. It is crucial to choose the combination therapy to be applied by taking these factors into consideration. In this review, current drug resistance mechanisms were discussed and then mechanisms of conventional chemotherapy related resistance were explained.